nicotinamide/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) score
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“At week 48, nicotinamide-treated participants experienced less decline on CDR-SB (mixed-effect model with repeated measures; estimate = -1.42, SE = 0.65; p = 0.03 unadjusted for multiple comparisons), without significant differences in cognitive (ADAS-cog; estimate = -1.93, SE = 1.93; p = 0.32) or functional (ADCS-ADL-MCI; estimate = -3.10, SE = 1.86; p = 0.10) outcomes.”
Quoted verbatim from Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.. - Study
- RCT
- Duration
- 11 months
- Dose
- 1,500 mg twice daily
- Population
- Adults with mild cognitive impairment or mild dementia with CSF biomarker-confirmed Alzheimer disease, nicotinamide versus placebo
Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.2025PMID:39671543Permalink
Keep reading
- Everything the graph holds on nicotinamide
- Every compound studied against Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) score
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PFZ4T3HTW5YV1F9WF2928H